Market Intelligence, Clinical Progress, and High-Purity Reagents for Allergy, Asthma, and Hematological Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD23/FCER2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD23/FCER2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD23 Products |
| Gene Delivery | CD23/FCER2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry and conformation-dependent binding assays. |
View CD23 Products |
| Benchmark Ab | Anti-CD23/FCER2 Recombinant Antibody Recombinant positive control based on clinical Benchmark (Lumiliximab sequence). |
View CD23 Products |
| Validator | CD23/FCER2 siRNA Set For target knockdown verification and specificity profiling. |
View CD23 Products |
| Related Target A | IgE (Immunoglobulin E) Natural ligand of CD23. Crucial for establishing IgE-CD23 binding inhibition assays. |
View IgE Products |
| Related Target B | CD20 (MS4A1) Co-target in B-cell malignancies. Frequently combined with CD23 targeting in CLL therapies. |
View CD20 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing membrane-bound CD23 from soluble CD23 (sCD23) | High-purity monomeric and oligomeric CD23 extracellular domain (ECD) proteins verified by SEC-HPLC. |
| Cross-species reactivity validation (Human/Cyno/Mouse) | Sequence-verified human, cynomolgus, and murine CD23 ortholog proteins with native glycosylation. |
| Lack of positive control reference standards | Sequence-derived clinical benchmark antibodies (Lumiliximab biosimilar) available for assay calibration. |
| Assay signal-to-noise ratio in B-cell screening | Lentivirus-mediated stable CD23-overexpressing cell lines bypass primary B-cell heterogeneity. |
Live CD23/FCER2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD23 (FCER2) is undergoing a major renaissance. Historically recognized as a key regulator of IgE synthesis in allergic diseases and a diagnostic marker in Chronic Lymphocytic Leukemia (CLL), CD23 is now being re-evaluated through modern therapeutic modalities. While early clinical efforts focused on first-generation monoclonal antibodies (such as Lumiliximab), current R&D pipelines are pivoting toward bispecific antibodies (e.g., CD23 x CD20, CD23 x IgE) and antibody-drug conjugates (ADCs) designed to selectively deplete CD23-positive pathogenic B cells while sparing healthy tissue.
As drug developers transition from simple ligand-blocking mechanisms to effector-function-mediated clearance, the demand for highly characterized, native-conformation CD23 reagents has intensified. Specifically, differentiating therapeutic candidates that bind membrane-bound CD23 without cross-reacting with or being neutralized by circulating soluble CD23 (sCD23) remains a critical bottleneck in lead optimization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biogen, Genentech | CLL, Allergic Asthma, Atopic Dermatitis | Inhibition assays of IgE/CD23 interaction using high-purity monomeric CD23. |
| Bispecific / Multispecific | Academic Institutes, Biotech Startups | B-cell Malignancies, Severe Allergy | Simultaneous binding validation requiring dual-antigen target panels (CD23 + CD20 / IgE). |
| ADCs / Immunotoxins | Oncology-focused Biopharma | Refractory CLL, Follicular Lymphoma | Internalization assays utilizing Lentivirus-generated stable CD23-expressing cell lines. |